NOVO-CIMETINE INJECTION 150 MG
CIMETIDINE (CIMETIDINE HYDROCHLORIDE) : 150 MG · DIN 02209063 · TEVA CANADA LIMITED
Health Canada status: CANCELLED POST MARKET
What is NOVO-CIMETINE INJECTION?
NOVO-CIMETINE INJECTION 150 MG contains CIMETIDINE (CIMETIDINE HYDROCHLORIDE) : 150 MG. It is listed in the Health Canada Drug Product Database under DIN 02209063, held by TEVA CANADA LIMITED, supplied as SOLUTION for INTRAMUSCULAR ; INTRAVENOUS administration. Health Canada currently lists it as cancelled post market, status dated 30-Apr-2015. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is NOVO-CIMETINE INJECTION used for?
Duodenal/gastric ulcers, GERD, upper GI hemorrhage, Zollinger-Ellison Syndrome, stress ulcer prophylaxis, acid aspiration prophylaxis, cystic fibrosis adjunct, and NSAID-induced lesions.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
What else is NOVO-CIMETINE INJECTION called?
The same molecule, CIMETIDINE, is registered under other names elsewhere. Buyers and prescribers searching from outside Canada — or working from a foreign prescription or tender document — often know it by one of these:
| Name | Script | Registered in |
|---|---|---|
| TAGAMET | Latin | Morocco |
| ULCESTOP | Latin | Morocco |
| Lenamet | Latin | South Africa |
| ULCEMAT | Latin | Morocco |
| Cimlok | Latin | South Africa |
| Acidown | Latin | South Africa |
| CIMEDINE | Latin | Saudi Arabia |
| GASTROP | Latin | Morocco |
| Mexiena | Latin | South Africa |
| Cinadine | Latin | South Africa |
| Rolab-Cimetidine | Latin | South Africa |
| ULCEMID | Latin | Morocco |
Names are taken from national medicine registers and published price lists. A product registered abroad is not authorized for sale in Canada unless it holds its own DIN; import is possible only through the routes Health Canada permits.
Product details and regulatory record
| DIN | 02209063 |
|---|---|
| Brand name | NOVO-CIMETINE INJECTION |
| Generic / active ingredient | CIMETIDINE (CIMETIDINE HYDROCHLORIDE) : 150 MG |
| Manufacturer | TEVA CANADA LIMITED |
| Strength | 150 MG |
| Dosage form | SOLUTION |
| Route of administration | INTRAMUSCULAR ; INTRAVENOUS |
| Schedule | Prescription |
| ATC code | A02BA01 CIMETIDINE |
| AHFS class | 56:28.12 |
| Biosimilar | No |
| Health Canada status | CANCELLED POST MARKET |
| Status date | 30-Apr-2015 |
| Original market date | 1997-09-02 00:00:00 |
How is this product identified?
Purchase orders, customs paperwork and tender documents each ask for a different identifier, and a DIN written without its leading zeros is the single most common reason an order line fails to match. Every form Nexara accepts for this product is listed here.
| DIN (8-digit, as used in Nexara ordering) | 02209063 |
|---|---|
| DIN (unpadded, as printed on some documents) | 2209063 |
| Brand name | NOVO-CIMETINE INJECTION |
| Active ingredient / INN | CIMETIDINE (CIMETIDINE HYDROCHLORIDE) : 150 MG |
| ATC code | A02BA01 |
| ATC anatomical main group | A — Alimentary tract and metabolism |
| ATC therapeutic subgroup | A02 |
| AHFS class | 56:28.12 |
| Health Canada schedule | Prescription |
| Biosimilar biologic | No |
| Market authorization holder | TEVA CANADA LIMITED |
How is it administered?
Adults: 800-1200 mg/day (oral) for ulcers. GERD: 1.2 g/day. Injection: 300 mg every 6 hours IV/IM. Max 2400 mg/day. Dosage reduction required in renal impairment.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Tablets: 15-30°C, protect from light. Injection: 15-25°C, protect from light, do not refrigerate.
How is it supplied?
Tablets: Bottles of 100, 500, 1000; Unit Dose strips of 100. Injection: 2 mL single dose vials (300 mg/2 mL) in packs of 10.
Which pack is which?
| Strength on the label | 150 MG |
|---|---|
| Dosage form | SOLUTION |
| Route | INTRAMUSCULAR ; INTRAVENOUS |
| Packaging as described in the monograph | Tablets: Bottles of 100, 500, 1000; Unit Dose strips of 100. Injection: 2 mL single dose vials (300 mg/2 mL) in packs of 10. |
| Storage | Tablets: 15-30°C, protect from light. Injection: 15-25°C, protect from light, do not refrigerate. |
One DIN can cover more than one pack size, and the pack — not the DIN — is what gets priced, shipped and invoiced. Before an order line is unambiguous Nexara needs the strength, the pack size and the presentation, because this listing covers more than one of them.
Cold chain. This product is stored refrigerated. Nexara ships it on a validated cold chain with temperature monitoring; a delivery address that cannot receive and store it at 2–8 °C on arrival must be flagged before the order is placed.
Contraindications
Contraindicated in patients known to have hypersensitivity to the drug.
Warnings and precautions
Avoid rapid IV injection (risk of arrhythmia/hypotension). Symptomatic response does not exclude gastric malignancy. Use caution in elderly/severely ill (risk of confusion).
Is CIMETIDINE in shortage in Canada?
A Canadian shortage report is on file for a product containing this molecule: Resolved — reported by AA PHARMA INC, last seen 16 Jun 2026. A shortage on one presentation does not always affect every DIN of the molecule — the alternatives below list what else is marketed in Canada. Nexara can confirm current availability and identify substitutions or import options where permitted.
What can be used instead?
Other Canadian products sharing ATC code A02BA01 CIMETIDINE. 2 of 50 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| CIMETIDINE | 200 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00584215 |
| CIMETIDINE | 300 MG | TABLET | AA PHARMA INC | MARKETED | DIN 00487872 |
| APO-CIMETIDINE ORAL SOLUTION | 300 MG / 5 ML | LIQUID | APOTEX INC | CANCELLED POST MARKET | DIN 02243085 |
| CIMETIDINE | 400 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00600059 |
| CIMETIDINE | 600 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00600067 |
| CIMETIDINE | 800 MG | TABLET | AA PHARMA INC | DORMANT | DIN 00749494 |
| CIMETIDINE 200 TAB 200MG | 200 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00596469 |
| CIMETIDINE TAB 300MG | 300 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00596477 |
| CIMETIDINE TAB 400MG | 400 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00618691 |
| CIMETIDINE TAB 600MG | 600 MG | TABLET | PRO DOC LIMITEE | CANCELLED POST MARKET | DIN 00618705 |
Who else supplies CIMETIDINE worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. CIMETIDINE appears in 47 registered pack listings across 5 markets, published on 5 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How much does CIMETIDINE cost around the world?
CIMETIDINE is listed on 7 national price registers Nexara tracks, across 92 pack listings published on 7 different price bases. What each country publishes is set out below.
| Market | What that country publishes | Brands listed | Pack listings | As of |
|---|---|---|---|---|
| Morocco | PPV (public price) | 6 | 30 | 05 Sep 2026 |
| South Africa | single exit price | 16 | 27 | 01 Sep 2026 |
| United States | acquisition | 5 | 23 | 03 Sep 2026 |
| Saudi Arabia | public | 5 | 6 | 01 Sep 2026 |
| United Kingdom | hospital | 3 | 3 | 31 Aug 2026 |
| Greece | producer price (ex-factory) | 2 | 2 | 03 Sep 2026 |
| Iceland | max wholesale | 1 | 1 | 02 Sep 2026 |
Why there are no figures here. These bases are not comparable. A Brazilian ex-factory ceiling, a Belgian pharmacy public price and a Japanese reimbursement rate answer three different questions, and none of them is what a product lands in Canada for. Putting them side by side would mislead in both directions, so Nexara publishes where a molecule is listed and on what basis, and quotes the delivered Canadian price per order.
Can this still be bought in Canada?
No. This Drug Identification Number is cancelled post market in Health Canada's Drug Product Database, so the product is no longer authorized for sale in Canada and Nexara does not supply it. This page is kept as a regulatory record.
If you are looking for a current equivalent, the alternatives above list every product sharing this therapeutic class, with the marketed ones first. Ask us to source an alternative
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.